Amerikanische Gesellschaft für Hirudotherapie

Ministry of Health — State of Kuwait (Drug and Food Control Administration)

Kuwait MoH-DFC · Kuwait · middle east

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Kuwait's Ministry of Health, Drug and Food Control Administration — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
middle east
Country
Kuwait
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Kuwaiti Law No. 28 of 1996 on Practice of Pharmacy
  • Kuwaiti Ministry of Health Medical Devices Regulations
  • GCC harmonised Drug Registration Procedures (where applicable)

Prescriber Requirements

  • Kuwait Ministry of Health–licensed physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ministry of Health registration as applicable; Arabic and English-language labelling. Standard cold-chain conditions.

Import/Export Rules

Ministry of Health and Public Authority for Agriculture Affairs and Fish Resources clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Kuwait public health system coverage depends on inpatient bundling; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. GCC member states share elements of pharmaceutical regulatory harmonisation; whether this captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.